Analysts think QURE stock price could increase by 95%
Feb 09, 2026, 12:25 PM
-28.83%
What does QURE do
uniQure NV, headquartered in Amsterdam, specializes in gene therapies and employs 480 staff, focusing on one-time treatments for genetic diseases. Their lead candidates include AMT-061 for hemophilia B and AMT-130 for Huntington's disease.
14 analysts think QURE stock price will increase by 94.70%. The current median analyst target is $49.98 compared to a current stock price of $25.67. The lowest analysts target is $27.27 and the highest analyst target is $99.75.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.